Molecular and cellular pharmacology
Pharmacology of muscarinic acetylcholine receptor subtypes (m1–m5): high throughput assays in mammalian cells

https://doi.org/10.1016/0014-2999(95)00639-7Get rights and content

Abstract

Based on the ability of many receptors to amplify NIH 3T3 cells, we developed a high throughput assay of cloned receptor pharmacology. In this assay, receptors are transiently co-expressed with the marker enzyme β-galactosidase. Receptors that induce cellular proliferation select and amplify the cells that also express the marker, thus the ability of ligands to alter receptor activity are reported as changes in enzyme activity. We used this assay to evaluate the pharmacology of agonist and antagonist ligands for five cloned human muscarinic receptor subtypes (m1–m5). When cells were transfected with subtypes that prefer the G-protein Gq (m1, m3, m5) robust increases in enzyme activity were observed. The subtypes that prefer Gi (m2 and m4) only induced β-galactosidase when co-expressed with a chimera between the G-proteins Gq and Gi (Gq−i5). Overall, the rank-order of potency and intrinsic activity of most of the tested ligands were in remarkably good agreement with earlier results using cloned cell lines and isolated tissues. These data demonstrate that a high throughput colorimetric assay performed in 96-well plates can be used to evaluate subtle differences the pharmacology of ligands for cloned muscarinic receptor subtypes.

References (47)

  • S.V.P. Jones et al.

    Carbachol induces secretion in a mast cell line (RBL-2H3) transfected with the m1 muscarinic receptor gene

    FEBS Lett.

    (1991)
  • S. Lazareno et al.

    Pharmacological characterization of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors m1-m4

  • A.I. Levey

    Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain

  • M.N. Potenza et al.

    A method for evaluating the effects of ligands upon Gs protein-coupled receptors using recombinant melanophore-based bioassay

    Anal. Biochem.

    (1992)
  • R. Schwarz et al.

    Characterization of muscarinic agonists in recombinant cell lines

  • M. Wigler et al.

    Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells

    Cell

    (1977)
  • L.F. Allen et al.

    G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha-1B-adrenergic receptor enhances mitogenesis and tumorigenicity

  • O. Arunlakshana et al.

    Some quantitative uses of drug antagonists

    Br. J. Pharmacol. Chemother.

    (1959)
  • T.I. Bonner et al.

    Identification of a family of muscarinic acetylcholine receptor genes

    Science

    (1987)
  • N.J. Buckley et al.

    Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells

    Mol. Pharmacol.

    (1989)
  • Y.-C. Cheng et al.

    Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

    Biochem. Pharmacol.

    (1973)
  • B.R. Conklin et al.

    Substitution of three amino acids switches receptor specificity of Gqa to that of Gia

    Nature

    (1993)
  • Cited by (107)

    • Role of acetylcholine in control of sexual behavior of male and female mammals

      2014, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      More recently, it has been suggested that the sometimes perplexing effects of systemically-administered cholinergic drugs could relate instead to differences in drug affinities for mAChR subtypes (Floody, 2013; Floody and Lusk, 2013). In particular, some results suggest that OXO prefers M2 (or M2 and M4) receptors whereas SCO binds all subtypes to similar extents (Bräuner-Osborne and Brann, 1996; Dohanich et al., 1991; Ehlert and Tran, 1990; Gattu et al., 1997; Levey et al., 1991; Murakami et al., 1996; Vilaró et al., 1992, 1994). Such differences could explain several aspects of the effects on male sexual behavior, including (a) the relative specificity of the facilitation sometimes produced by OXO (Ahlenius and Larsson, 1985; Retana-Marquez et al., 1993), (b) the consistency with which SCO is able to reverse these effects (e.g., Ahlenius and Larsson, 1985), and (c) SCO's ability to sometimes go beyond a simple reversal by affecting additional measures and producing disproportionally large behavioral decrements (e.g., Retana-Marquez et al., 1993).

    • Responses to central oxotremorine and scopolamine support the cholinergic control of male mating behavior in hamsters

      2013, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      However, one possible dimension that may be relevant emerges from reports of possible differences in the relative affinities of OXO and SCO for the five or more receptors (M1–M5) thought to jointly mediate muscarinic responses. In particular, some results suggest a preference by OXO for M2, or M2 and M4, receptors that is not shared with SCO (e.g., Bräuner-Osborne and Brann, 1996; Ehlert and Tran, 1990; Gattu et al., 1997; Levey et al., 1991; Murakami et al., 1996; Pilar-Cuéllar et al., 2008; Sánchez et al., 2009; Thomsen et al., 2010; Vilaró et al., 1992, 1994). A difference of this sort would have a variety of implications.

    View all citing articles on Scopus
    View full text